BRASILIA, Jan 7 (Reuters) – Brazil is in the process of closing a deal for up to 100 million doses of the COVID-19 vaccine developed by China’s Sinovac Biotech and finished in Brazil by Sao Paulo’s Butantan biomedical center, the health minister said Thursday.
Health Minister Eduardo Pazuello said the Chinese vaccine, called CoronaVac, will be included in Brazil’s national immunization plan, along with 100 million doses of AstraZeneca’s vaccine, to be finished at federal biomedical center Fiocruz and delivered by June.
Speaking at a news conference, Pazuello said liability, production and sovereignty issues were preventing Brazil from reaching a deal to buy doses of a COVID-19 vaccine made by Pfizer. (Reporting by Anthony Boadle and Gabriel Stargardter Editing by Brad Haynes)
Our Standards: The Thomson Reuters Trust Principles.
- Sinovac vaccine 78% effective [https://dailyasianage.com/news/251845/sinovac-vaccine-78-effective]
- COVID-19 vaccine produced in São Paulo 78% effective [https://anba.com.br/en/covid-19-vaccine-produced-in-sao-paulo-78-effective/]
- Peru: Armed Forces to guarantee security for COVID-19 vaccination [https://andina.pe/ingles/noticia-peru-armed-forces-to-guarantee-security-for-covid19-vaccination-829008.aspx]
- Highly possible that a Covid vaccine could be produced in SA [https://www.iol.co.za/news/south-africa/gauteng/highly-possible-that-a-covid-vaccine-could-be-produced-in-sa-21718e91-acd2-5922-b108-6fba8524e233]